Bosentan: In Pediatric Patients with Pulmonary Arterial Hypertension

Author： Carter Natalie J.   Keating Gillian M.  

Publisher： Adis International

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.12, Iss.1, 2010-02, pp. : 63-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term benefits of bosentan in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1404, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Bosentan: haemodynamic role in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1604, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses

By Karavolias George K   Georgiadou Panagiota   Gkouziouta Angeliki   Kariofillis Panagiotis   Karabela Georgia   Tsiapras Dimitrios   Sbarouni Eftihia   Chaidaroglou Antigoni   Degiannis Dimitrios   Adamopoulos Stamatis   Voudris Vassilis  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 12, 2010-12 ,pp. : 1283-1289

Informa Healthcare

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite